NASDAQ$CDNA
CareDx Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Reported a net loss, but testing volume and patient digital solutions showed momentum.
CareDx reported a revenue increase of 9% year-over-year, reaching $80.6 million. The company delivered 45,000 patient test results, a 21% increase compared to Q2 2021. However, the company experienced a net loss of $21.7 million, compared to a net loss of $1.9 million in the same period last year.
- Delivered 45,000 patient test results, representing growth of 21% compared to second quarter of 2021
- Achieved revenue of $80.6 million, increasing 9% year-over-year
- Sustained strong overall GAAP gross margin of 66%
- Project to achieve profitable growth with positive adjusted EBITDA by first half of 2023
Headline financials
Revenue & EPS history
CareDx · Revenue · Quarterly
$80.6M
Revenue by segment
CareDx · $73.8M total across 2 segments · Q2 2022
- Testing Services$67.1M+3.4%90.9%
- Product Revenue$6.7M-2.9%9.1%
Forward guidance
CareDx is revising revenue expectations to be in the range of $325 million to $335 million due to higher than expected mix of commercial patients from the success of new launches and market expansion.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
+2.4%
Avg return
Earnings day
+0.1%
Avg return
5 days after
+7.1%
Avg return
30 days after
54%
28 / 52 earnings
Positive
+45.7%
Q1 2024
Best reaction
-24.3%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.3% | -1.6% | +3.8% | |
| Q4 2025 | -4.3% | -2.6% | -12.8% | |
| Q3 2025 | -1.8% | +5.8% | +31.4% | |
| Q1 2025 | -10.7% | -16.0% | +0.7% | |
| Q4 2024 | -0.2% | -3.8% | -14.9% | |
| Q3 2024 | +1.1% | +4.5% | +14.5% | |
| Q2 2024 | +25.7% | +26.3% | +63.8% | |
| Q1 2024 | +45.7% | +49.7% | +49.4% | |
| Q4 2023 | +12.1% | +27.3% | +11.6% | |
| Q3 2023 | +8.7% | +19.5% | +48.0% | |
| Q2 2023 | -9.3% | -17.6% | -23.5% | |
| Q1 2023 | -2.0% | -2.2% | -8.7% | |
| Q4 2022 | +16.4% | -37.9% | -37.0% | |
| Q3 2022 | -16.5% | -14.4% | -31.1% | |
| Q2 2022 | +7.7% | -4.2% | -25.2% | |
| Q1 2022 | -24.3% | -32.1% | -23.9% | |
| Q4 2021 | +10.3% | +7.2% | +6.6% | |
| Q3 2021 | -24.3% | -26.9% | -37.1% | |
| Q2 2021 | -2.5% | -4.9% | -7.4% | |
| Q1 2021 | -1.9% | -10.0% | +9.3% | |
| Q4 2020 | +2.7% | +13.2% | -20.3% | |
| Q3 2020 | -3.1% | -2.4% | +13.5% | |
| Q2 2020 | +5.2% | -0.9% | -4.3% | |
| Q1 2020 | -0.0% | +9.6% | +19.6% | |
| Q4 2019 | -5.6% | -13.2% | -11.5% | |
| Q3 2019 | -11.8% | -23.8% | -21.6% | |
| Q2 2019 | +6.8% | -15.7% | -30.4% | |
| Q1 2019 | +15.0% | +12.6% | +30.6% | |
| Q4 2018 | +7.5% | +10.2% | -10.1% | |
| Q3 2018 | -9.8% | -10.2% | -6.0% | |
| Q2 2018 | +15.3% | +14.6% | +73.1% | |
| Q1 2018 | -2.1% | -2.6% | +35.1% | |
| Q4 2017 | +24.1% | +28.5% | +51.8% | |
| Q3 2017 | +6.2% | +6.6% | +31.0% | |
| Q2 2017 | +9.2% | +26.8% | +109.9% | |
| Q1 2017 | -4.6% | -3.7% | +14.7% | |
| Q4 2016 | +5.1% | -12.2% | +13.7% | |
| Q3 2016 | +1.3% | +3.9% | -24.7% | |
| Q2 2016 | -1.0% | -2.9% | -5.3% | |
| Q1 2016 | +6.0% | — | — | |
| Q4 2015 | +7.7% | — | — | |
| Q3 2015 | +5.0% | — | — | |
| Q2 2015 | -1.6% | — | — | |
| Q1 2014 | -0.4% | — | — | |
| Q1 2015 | -0.8% | — | — | |
| Q4 2012 | +0.5% | — | — | |
| Q4 2014 | -1.8% | — | — | |
| Q3 2013 | -1.0% | — | — | |
| Q3 2014 | +17.2% | — | — | |
| Q2 2013 | +0.2% | — | — | |
| Q4 2013 | +0.2% | — | — | |
| Q2 2014 | +1.9% | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro